By Measuring The Effect On A Living Organism, Tissue, Or Cell Patents (Class 506/10)
  • Patent number: 10392649
    Abstract: A polypeptide biosensor that detects free NAD+ is disclosed. The polypeptide comprises a first fragment from an NAD+ dependent DNA ligase acetylation domain, a second fragment from the NAD+ dependent DNA ligase acetylation domain, and a fluorescent protein, wherein the fluorescent protein is positioned between the two DNA ligase acetylation domain fragments. Also disclosed are expression vectors comprising the biosensor as well as methods of using the biosensor to detect NAD+.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 27, 2019
    Assignee: Oregon Health & Science University
    Inventors: Richard Goodman, Michael Cohen, Lulu Cambronne, Melissa Stewart
  • Patent number: 10384207
    Abstract: Apparatus and methods for determining whether a test compound induces cell activity, changes cell activity, prevents cell activity, or inhibits cell activity. An embodiment comprises placing a test compound solution in contact with a cell suspension media containing cells, diffusing the test compound solution into the cell suspension from one or more sides, and detecting activity in the cells with respect to their distance from the side from which the test compound is diffusing. Embodiments may provide an apparatus that allows a side source, a point source, or both, from which a test compound solution diffuses into a cell suspension media and contacts cells. Detecting cell activity may involve detecting activity in a first cell group proximate to the side from which the test compound is diffusing, and detecting activity in a second cell group farther than the first cell group from the side from which the test compound is diffusing.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: August 20, 2019
    Assignee: Neuro Probe Incorporated
    Inventor: Richard H. Goodwin, Jr.
  • Patent number: 10316293
    Abstract: The present invention relates to the field of pluripotent stem cell culture and methods facilitate pluripotent stem cell culture at industrial levels.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: June 11, 2019
    Assignee: Janssen Biotech, Inc.
    Inventor: Shelley Nelson
  • Patent number: 10246680
    Abstract: The present invention provides compositions and methods for the culture and maintenance of pluripotent stem cells. More particularly, the present invention provides for compositions and methods for culturing, maintaining, growing and stabilizing primate pluripotent stem cells in a feeder-free defined media further comprising human serum, or a soluble attachment component of the human serum, for promoting cell attachment.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: April 2, 2019
    Assignee: VIACYTE, INC.
    Inventors: Allan J Robins, Thomas C Schulz
  • Patent number: 10227587
    Abstract: The disclosure relates to a method for constructing a plasma Deoxyribonucleic acid (DNA) sequencing library. The method includes: extracting a plasma DNA; making the plasma DNA ligate to a sequencing linker, and purifying a ligation product; performing Polymerase Chain Reaction (PCR) amplification for the purified ligation product, purifying the PCR amplification product, and obtaining the plasma DNA sequencing library, wherein, the method does not include the step of performing 5?-terminus phosphorylation for the plasma DNA.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: March 12, 2019
    Assignee: Berry Genomics Co., Ltd.
    Inventors: Jianguang Zhang, Yang Gao, Yanbin Shi, Di Chen, Feng Tian
  • Patent number: 10053692
    Abstract: Described herein are methods and assays relating to the presence and/or level of circulating tumor cells (CTCs). These CTC-Cs represent a highly metastatic subpopulation of CTCs. In some embodiments, the methods and assays described herein relate to the treatment of cancer.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: August 21, 2018
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Nicola Aceto, Daniel Arie Haber, Shyamala Maheswaran
  • Patent number: 10000807
    Abstract: The disclosure describes the effects of transcription mediated from a promoter on the transcription mediated by divergently coupled supercoiling-sensitive promoter. Transcription initiated from a promoter inhibits transcription mediated by a specific supercoiling-sensitive promoter that is divergently coupled to the promoter. A gyrase inhibitor relieves this inhibition and substantially increases the transcription mediated by the specific supercoiling-sensitive promoter that is divergently coupled to another promoter. Accordingly, the invention pertains to a method for identifying a compound as a gyrase inhibitor or not a gyrase inhibitor based on differential expression of genes under the control of divergently coupled promoters in the presence of the compound. Another embodiment of the invention provides an assay for identifying one or more compounds from a library of compounds as a gyrase inhibitor.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 19, 2018
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Fenfei Leng, Xiaoduo Zhi, Samantha Dages, Kelley Dages
  • Patent number: 9983195
    Abstract: Described are three-dimensional, engineered, biological breast tissues, adipose tissues, and tumor models, including breast cancer models.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: May 29, 2018
    Assignee: Organovo, Inc.
    Inventors: Shelby Marie King, Deborah Lynn Greene Nguyen, Vivian A. Gorgen, Benjamin R. Shepherd, Sharon C. Presnell
  • Patent number: 9957506
    Abstract: Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: May 1, 2018
    Assignee: Cornell University
    Inventors: Juan R. Cubillos-Ruiz, Laurie H. Glimcher
  • Patent number: 9850483
    Abstract: Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: December 26, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael F. Clarke, Stephen R. Quake, Piero D. Dalerba, Huiping Liu, Anne A. Leyrat, Tomer Kalisky, Maximilian Diehn, Michael Rothenberg, Jianbin Wang, Neethan Lobo
  • Patent number: 9822184
    Abstract: Certain embodiments are directed to composition and methods related to DCLK1-S specific binding agents.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 21, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Pomila Singh, Shubhashish Sarkar, Malaney O'Connell
  • Patent number: 9816928
    Abstract: This invention provides biosensors, cell models, and methods of their use for monitoring heme and oxygen. Biosensors can include targeting domains, sensing domains and reporting domains. Biosensors can be introduced into cells reprogrammed to represent experimental or pathologic cells of interest. Model cells expressing the biosensors can be contacted with putative bioactive agents to determine possible activities.
    Type: Grant
    Filed: November 26, 2016
    Date of Patent: November 14, 2017
    Assignee: Tempo Bioscience Inc.
    Inventor: Angela Huang
  • Patent number: 9803167
    Abstract: The present disclosure relates to stretching apparatus and method for aligning microfibrils. Specifically, the present disclosure provides an apparatus for aligning microfibrils along a single direction, which includes: a first elastic substrate onto which a composition containing microfibrils is loaded; and a stretching module which stretches the width of the elastic substrate. In accordance with the apparatus the present disclosure, microfibrils or cells may be aligned along a particular direction simply by pulling and then releasing the elastic substrate. The present disclosure is also useful for culturing of the aligned cells because the physiological activity of the cells can be maintained and cytotoxicity can be prevented.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: October 31, 2017
    Assignee: Korea Institute of Science and Technology
    Inventors: Nakwon Choi, Eun-Mi Hur, Sohyun Kim, Sun-Kyoung Im, Eui Sung Yoon, Changjoon Justin Lee
  • Patent number: 9657360
    Abstract: The present invention relates to methods of detecting an increased likelihood of virus infection in a subject. In particular, the present invention relates to methods of detecting an increased likelihood of virus infection in a subject by detecting an altered level of at least one microRNA (miRNA), as well as methods of treating or preventing virus infection. The present invention also relates to nucleotide arrays, oligonucleotides and kits useful for the detection of miRNAs associated with an increased likelihood of virus infection in a subject.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 23, 2017
    Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: Cameron Stewart, Andrew Bean
  • Patent number: 9518979
    Abstract: A novel assay using plated (cultured) human hepatocytes is disclosed. In this assay, cryopreserved human hepatocytes are thawed and cultured for 4 hours to allow attachment, followed by incubation with compounds for 24 hours. After the 24 hour incubation, aliquots can be collected for quantification of the remaining parent compounds. The remaining incubated media are transferred to freshly thawed and cultured cryopreserved hepatocyte and incubated for another 24 hour period. The process can be repeated daily resulting in accumulated incubation durations of multiple days. The innovation is the use of a new culture on each day, thereby overcoming the known decrease in metabolic activity of hepatocytes with time in culture.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: December 13, 2016
    Inventor: Albert P Li
  • Patent number: 9365640
    Abstract: Uses of the protein cereblon as a predictor of clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: June 14, 2016
    Assignee: CELGENE CORPORATION
    Inventors: Antonia Lopez-Girona, Peter H. Schafer, Anita Gandhi, Derek Mendy, Thomas O. Daniel
  • Patent number: 9255124
    Abstract: The disclosed invention relates to methods of modifying peptide compositions to increase stability and delivery efficiency. Specifically, the disclosed invention relates to methods to increase the stability and delivery efficiency of protein kinase C (PKC) modulatory peptide compositions. A “therapeutic peptide composition” comprises a “carrier peptide” and a “cargo peptide.” A “carrier peptide” is a peptide or amino acid sequence within a peptide that facilitates the cellular uptake of the therapeutic peptide composition. The “cargo peptide” is a PKC modulatory peptide. Peptide modifications to either the carrier peptide, the cargo peptide, or both, which are described herein increase the stability and delivery efficiency of therapeutic peptide compositions by reducing disulfide bond exchange, physical stability, reducing proteolytic degradation, and increasing efficiency of cellular uptake.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: February 9, 2016
    Assignee: KAI PHARMACEUTICALS, INC.
    Inventor: Derek Maclean
  • Patent number: 9186673
    Abstract: Multi-well plates having contoured well designs allow multi-stage high throughput parallel assaying of ion channels or ion transporters. A well of a multi-well plate has a bottom region that is sized and shaped to simultaneously accommodate a sensing electrode and a pipette for delivering test compounds, wash fluid, and optionally ligands. The multi-well plates when coupled with an instrument having a pipette head and an electrode plate facilitates fluidic contact between cells and fluids delivered via a pipette for washing of wells with buffers or other wash solutions for serial exposure of test cells to various reagents or other stimuli. The control and test experiments are performed on the same cell (or cells) in a single well.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 17, 2015
    Assignee: Molecular Devices, LLC
    Inventor: Edward D. Verdonk
  • Patent number: 9183350
    Abstract: Apparatus, methods, and other embodiments associated with objectively predicting biochemical recurrence (BCR) with cell orientation entropy (COrE) are described. One example apparatus includes a set of logics that associate directional disorder with a risk of biochemical recurrence in a tissue. A first logic detects a cell in the tissue, segments boundaries of the cell, and calculates a cell direction for the cell. A second logic constructs a localized sparsified subgraph whose nodes represent centroids of the cells, defines pairwise spatial relationships between the cells, and constructs a directional co-occurrence matrix based on the spatial relationships. A third logic derives second order statistical features from the co-occurrence matrix, and produces a BCR risk score as a function of the second order statistical features. The second order statistical features include the entropy of the directional organization of the cells.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: November 10, 2015
    Inventors: Anant Madabhushi, George Lee, Sahirzeeshan Ali, Rachel Sparks
  • Patent number: 9163263
    Abstract: The invention provides for compositions and methods for producing isoprene using isoprene synthase variants with improved properties.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 20, 2015
    Assignees: The Goodyear Tire & Rubber Company, Danisco US Inc.
    Inventors: Zachary Q. Beck, David A. Estell, Jeffrey V. Miller, James Ngai, Christopher L. Rife, Derek H. Wells
  • Patent number: 9150850
    Abstract: The present invention relates to compositions and methods for analyzing and modulating (e.g., enhancing or inhibiting) protein-protein interactions. In particular, compositions and methods of the present invention find use in identifying, reconstituting and characterizing protein-protein interactions, identifying binding subunits, and drug screening. The methods and compositions of the invention may also be used to identify agents that may agonize or antagonize a protein-protein interaction (e.g., using test compounds).
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: October 6, 2015
    Assignees: CORNELL RESEARCH FOUNDATION, INC., RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Matthew DeLisa, George Georgiou, Dujduan Waraho
  • Patent number: 9153024
    Abstract: A method and system for predicting spatial and temporal distributions of therapeutic substance carriers within a body of a user, comprising: at a computing system, receiving an image dataset and a spectra dataset of a therapeutic substance carrier generated from at least one of an imaging model and a spectra-generating module; transforming the image dataset and the spectra dataset into a set of characteristics, wherein the set of characteristics comprises electrotopological characteristics and geometrical characteristics; generating a set of pharmacokinetic parameters and a set of pharmacodynamic parameters for the therapeutic substance carrier based upon the set of characteristics and a transformation model; and transforming the set of pharmacokinetic parameters and the set of pharmacodynamic parameters into a spatial distribution and a temporal profile of the therapeutic substance carrier, based upon a predictive model incorporating physiological parameters of the body, thereby predicting distributions of t
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: October 6, 2015
    Assignee: CRIXlabs, Inc.
    Inventor: Shalini Ananda Yogendran
  • Publication number: 20150148256
    Abstract: A bioluminescence imaging-based high-throughput assay for inhibitors of ABCG2 is described. Compositions of inhibitors of ABCG2 and methods of using ABCG2 inhibitors are also described.
    Type: Application
    Filed: August 21, 2014
    Publication date: May 28, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN GILBERT POMPER, YIMAO ZHANG, JOHN LATERRA
  • Publication number: 20150140075
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150141284
    Abstract: The invention relates to the field of medicine. The invention provides methods for generating glatiramer-acetate-specific human T-cell lines, and assays that use these T-cell lines for demonstrating immunological identity between glatiramer acetate preparations. These assays allow sensitive and accurate comparison of glatiramer acetate preparations, and find utility as lot-release assays.
    Type: Application
    Filed: October 23, 2014
    Publication date: May 21, 2015
    Inventors: Jeffrey P. Smith, Peter E. Lipsky, Anne Lodge
  • Publication number: 20150143557
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Application
    Filed: September 22, 2014
    Publication date: May 21, 2015
    Inventors: KENYA HONDA, KOJI ATARASHI, KIKUJI ITOH, TAKESHI TANOUE
  • Publication number: 20150141470
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a MAPK pathway inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and a GEF or HDAC inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a MAPK inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and an effective amount of a GEF or HDAC inhibitor. A method of identifying targets that confers resistance to a MAPK pathway inhibitor is also provided.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 21, 2015
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Cory M. Johannessen
  • Publication number: 20150140015
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of pancreatic cancers. In particular, the present invention relates to an OX1R agonist for use in the treatment of pancreatic cancer in a subject in need thereof.
    Type: Application
    Filed: January 20, 2015
    Publication date: May 21, 2015
    Inventor: Thierry VOISON
  • Publication number: 20150143577
    Abstract: The present invention provides methods and compositions for the identification and selection of loci modulating phenotypic expression of an herbicide tolerance trait in plant breeding. In addition, methods are provided for screening germplasm entries for the performance and expression of this trait.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 21, 2015
    Applicant: Monsanto Tecnology LLC
    Inventors: Mindy L. DeVries Gelder, Paul Feng, Jesse J. Gilsinger, Floyd G. Hancock, Ivan Husic, James Narvel, Curtis W. Scherder, Dean A. Ulbrich
  • Publication number: 20150141289
    Abstract: The invention provides for compositions and methods for identifying and validating modulators of cell fate, such as such as maintenance, cell specification, cell determination, induction of stem cell fate, cell differentiation, cell dedifferentiation, and cell trans-differentiation. The invention relates to reporter nucleic acid constructs, host cells comprising such constructs, and methods using such cells and constructs. The invention relates to methods for making cells comprising one or more reporter nucleic acid constructs using fluorogenic oligonucleotides. The methods relate to high throughput screens.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Inventors: Kambiz Shekdar, Dennis J. Sawchuk, Jessica C. Langer
  • Publication number: 20150140077
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150133524
    Abstract: The invention provides therapeutic and prophylactic compounds and methods for altering the activity of pyruvate dehydrogenase kinase (e.g. PDK1, PDK2, PDK3, PDK4). Such therapies are useful for the treatment of neoplasia. The invention further provides therapeutic and prophylactic compounds and methods of altering pyruvate dehydrogenase activity to treat or prevent cell death related to ischemia.
    Type: Application
    Filed: October 15, 2014
    Publication date: May 14, 2015
    Inventors: Chi V. Dang, Jung-whan Kim, Gregg L. Semenza
  • Publication number: 20150133341
    Abstract: The present invention is concerned with an in vitro method of diagnosing cancer in a tissue sample, wherein said tissue sample is obtained from a patient undergoing cancer surgery. The method described herein is based on a hyperpolarized marker, which is contacted with the tissue sample, and an NMR spectrum and/or an MR image obtained of the tissue sample after having been contacted with the hyperpolarized marker.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 14, 2015
    Inventors: Mathilde Lerche, Magnus Karlsson, Pernille Rose Jensen
  • Publication number: 20150133441
    Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 14, 2015
    Inventor: Gerard M. Housey
  • Publication number: 20150133340
    Abstract: The present invention relates to a method of determining the risk of drug induced teratogenicity using pluripotent stem cells.
    Type: Application
    Filed: March 4, 2013
    Publication date: May 14, 2015
    Inventors: Eric Chiao, Sei Kameoka, Kyle L. Kolaja
  • Publication number: 20150135358
    Abstract: Transgenic seed for crops with enhanced agronomic traits are provided by trait-improving recombinant DNA in the nucleus of cells of the seed where plants grown from such transgenic seed exhibit one or more enhanced traits as compared to a control plant. Of particular interest are transgenic plants that have increased yield. The present invention also provides recombinant DNA molecules for expression of a protein, and recombinant DNA molecules for suppression of a protein.
    Type: Application
    Filed: October 24, 2014
    Publication date: May 14, 2015
    Inventors: Maria C. Bohannon, Marie Coffin, Amanda Winslow, Faten Shaikh
  • Publication number: 20150133339
    Abstract: This invention provides a multiscale platform for coordinating behavior using synthetic biology. The platform reduces the impact of underlying noise, making outputs more coherent and reliable at the macroscopic level.
    Type: Application
    Filed: December 14, 2012
    Publication date: May 14, 2015
    Applicant: The Regents of the University of California
    Inventors: Arthur Prindle, Phillip Samayoa, Jeff Hasty
  • Publication number: 20150125441
    Abstract: The present invention provides methods of treating and pharmaceutical compositions useful for treating a mood disorder or depressive symptoms associated with pain, inducing analgesia and treating pain in a subject by administering a pharmaceutically effective amount of an agent capable of one or more of increasing GluA1 level, expression, concentration, or biological activity, increasing calcium permeable AMPA (? amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor (CPAR) level, expression, concentration, or biological activity or potentiating a CPAR current. The agent may be an AMPA potentiator or ampakine. The agent may increase AMPA receptor currents by slowing the deactivation of open channels and may be, for instance, 2-pyrrolidinone, 4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluorophenoxyacetamide (PEPA) or LY451646. The agent may also be a protein, RNA or DNA product.
    Type: Application
    Filed: May 24, 2013
    Publication date: May 7, 2015
    Applicant: New York University
    Inventors: Jing Wang, Edward Ziff
  • Publication number: 20150126398
    Abstract: Dendritic cell precursor populations, dendritic cell populations derived therefrom, methods for isolating, expanding and using are disclosed.
    Type: Application
    Filed: December 30, 2014
    Publication date: May 7, 2015
    Applicant: THE UNIVERSITY OF TOLEDO
    Inventors: Akira Takashima, Hironori Matsushima, Shuo Geng
  • Publication number: 20150118247
    Abstract: The invention relates to immunomodulation of cells and the detection and use thereof, for example, in drug screening, including methods, compositions and systems therefor, or in an aspect of healthcare, such as prognosis, diagnosis, an aspect of treatment, monitoring, and the like, and methods, compositions, and systems therefor.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 30, 2015
    Inventors: Drew Hotson, Rachael Hawtin, Andy Conroy, Erwan Le Scolan
  • Publication number: 20150119327
    Abstract: The invention provides a method for restoring a neural cell having a deficiency or alteration in glutamatergic pathway affecting neuron and/or glial function comprising contacting the cell with a NMDA receptor antagonist(s) and/or modulator(s) of a glutamatergic pathway, thereby restoring the neural cell having a deficiency or alteration in glutamatergic pathways affecting neuron and/or glial function.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 30, 2015
    Inventors: Alysson Renato Muotri, Cassiano Carromeu, Allan Acab
  • Publication number: 20150119274
    Abstract: The present invention describes microplates with arrays of wells containing magnetic inserts in the form of disks, cylinders or otherwise shaped materials with apertures in the centre for optical interrogation of the contacting solution. These inserts are capable of capturing ferro- and paramagnetic nano- and microparticles. The subject microplates find use in a variety of applications, including clinical and environmental assays, high throughput screening for genomics, proteomics and pharmaceutical applications, point-of-care in vitro diagnostics, molecular genetic analysis and nucleic acid diagnostics, cell separations, and bioresearch generally and high-throughput screening of materials for separation and catalysis.
    Type: Application
    Filed: June 3, 2013
    Publication date: April 30, 2015
    Inventors: Sergey Anatoliyovich Piletsky, Olena Piletska, Antonio Guerreiro, Alessandro Poma, Khalku Karim, Stanislav Piletsky
  • Publication number: 20150119557
    Abstract: We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially T-cell acute lymphoblastic leukemia lymphoma (T-ALL), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor.
    Type: Application
    Filed: April 12, 2013
    Publication date: April 30, 2015
    Applicants: THE UNIVERSITY OF MIAMI, THE BRITISH COLUMBIA CANCER AGENCY BRANCH, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Andrew P. Weng, Jon C. Aster, Tan A. Ince
  • Publication number: 20150119441
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: November 4, 2014
    Publication date: April 30, 2015
    Inventors: Sara S. Hadida Ruah, Peter D.J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Jamel Numa, Xiaoqing Yang
  • Publication number: 20150118191
    Abstract: The present invention provides methods of designing panels of bacteriophages as therapeutic compositions against bacterial infections. The present invention also provides panels of bacteriophages for use in the prevention or treatment of bacterial infections.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 30, 2015
    Inventors: David Harper, Katy Blake
  • Publication number: 20150119284
    Abstract: Disclosed is a microcapsule encoded depending on the kind of a target substance included therein. The encoded microcapsule has a hydrophilic liquid core including the target substance and a hydrophobic shell surrounding the liquid core. The encoded microcapsule includes graphical codes introduced on the surface of the shell.
    Type: Application
    Filed: October 28, 2013
    Publication date: April 30, 2015
    Applicant: SNU R&DB FOUNDATION
    Inventors: Sunghoon KWON, Younghoon SONG, Taehong KWON, Daewon LEE, Junhoi KIM
  • Publication number: 20150113680
    Abstract: This disclosure provides purified nucleic acids and polypeptides. Also provided are transgenic plants, seeds, and plant cells containing DNA for expression of the proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants, methods of making such plants and methods of making agricultural commodity including seeds and hybrid seeds from such plants.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 23, 2015
    Applicant: MONSANTO TECHNOLOGY LLC
    Inventors: David K. KOVALIC, Jack E. TABASKA, Bo-Xing QIU, Wei WU
  • Publication number: 20150110736
    Abstract: An embodiment of the present invention is a method for subjecting a hematopoetic cell to a JAK/STAT inhibitor, determining the activity of gain-of-function mutations of a Jak family kinase, determining the expression levels and activity of JAK/STAT regulatory proteins, correlating the expression levels and the activity of JAK/STAT regulatory proteins with the activity of gain-of-function mutations of a Jak family kinase and with a response to the JAK/STAT inhibitor, and then classifying the cells. A further embodiment of the invention includes determining the clinical outcome based on the cell classification, determining a method of treatment, determining dosing and scheduling of at least one of the JAK/STAT inhibitors or other compounds.
    Type: Application
    Filed: June 3, 2014
    Publication date: April 23, 2015
    Applicant: Nodality, Inc.
    Inventors: Wendy J. FANTL, Alessandra CESANO, Todd COVEY
  • Patent number: 9012202
    Abstract: Embodiments of the present disclosure provide for arrays, systems, and methods for the analyzing cells, methods of making arrays, and the like.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: April 21, 2015
    Inventors: Benjamin George Keselowsky, Abhinav Prakash Acharya, Emina Huang, Edward William Scott, Matthew Carstens
  • Patent number: 9012172
    Abstract: The present invention provides high throughput assays for identifying compounds that modulate a contractile function, as well as devices suitable for use in these assays.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: April 21, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Kevin Kit Parker, Adam Walter Feinberg, Patrick W. Alford, Anna Grosberg, Mark D. Brigham, Josue Adrian Goss